PULSE BIOSCIENCES, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho Securities USA LLC (“Mizuho”) as sales agent, pursuant to which the Company may o
Wealthfront (WLTH) shares rose 6.6% to $10.08 after reporting Q2 earnings of $0.10 per share, beating estimates. Other stocks gaining include Orchestra BioMed (OBIO) +8.4%, AeroVironment (AVAV) +7.2%, and Molina Healthcare (MOH) +6.1%.
Pulse Biosciences (PLSE) stock rose 10% after analyst Keith Hinton initiated coverage with a buy rating and $73 price target, citing potential in atrial fibrillation ablation. Hinton highlights the company's proprietary NPS technology and strong cash position, with clinical trials underway. Success could lead to a buyout by mid-2027, according to the analyst.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PLSE (PULSE BIOSCIENCES, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PLSE coverage spans earnings, market movers and insider activity.
In the last 30 days, PLSE insiders filed 4 SEC Form 4 transactions — 4 purchases ($200K) and no sales. The most active reporter was Teplitsky Liane Rae, Chief Operating Officer, with 4 filings.
Potential cash infusion of up to $85M with dilution risk; no immediate sales obligation.
New coverage may drive near-term buying.
Analyst initiation and positive price target drive short-term buying pressure.
Unexplained price move may reflect speculative buying on trial momentum.
Losses and modest revenue may pressure the stock, but trial progress offers upside.
AlphAI scores every news story that mentions PLSE with an AI model for sentiment and relevance, and aggregates insider trades from PULSE BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho Securities USA LLC (“Mizuho”) as sales agent, pursuant to which the Company may o
1 min readWealthfront (WLTH) shares rose 6.6% to $10.08 after reporting Q2 earnings of $0.10 per share, beating estimates. Other stocks gaining include Orchestra BioMed (OBIO) +8.4%, AeroVironment (AVAV) +7.2%, and Molina Healthcare (MOH) +6.1%.
2 min readPulse Biosciences (PLSE) stock rose 10% after analyst Keith Hinton initiated coverage with a buy rating and $73 price target, citing potential in atrial fibrillation ablation. Hinton highlights the company's proprietary NPS technology and strong cash position, with clinical trials underway. Success could lead to a buyout by mid-2027, according to the analyst.
2 min readOpus Genetics (IRD) rose 27% after positive clinical trial data. Quantum (QNTM) gained 10% with FDA Phase 2 trial clearance. Pulse Biosciences (PLSE) surged 15% without specific news. Decoy Therapeutics (DCOY) and ONWARD Medical (ONWD.BR) also traded higher on updates.
3 min readModular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga
3 min readTeplitsky Liane Rae (Chief Operating Officer) purchased 2,025 shares of PULSE BIOSCIENCES, INC. (PLSE) at an average of $49.37 ($48.80–$49.95) across 2 trades over 2026-08-31 to 2026-09-01.
1 min readSeveral biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.
2 min readOn August 28, 2026, notable insider trading included Optimum Communications (OPTU) director Neil S. Subin buying $2.45M in shares, REGENXBIO (RGNX) director Gregory Austin Ciongoli purchasing $949K, and Pulse Biosciences (PLSE) COO Liane Rae Teplitsky acquiring $99K. United States Antimony (UAMY) CEO Gary C. Evans bought $98K in shares, while Battalion Oil (BATL) director William D. Rogers purchased $91K. On the sell side, Life Time Group (LTH) insiders sold $126M, Relay Therapeutics (RLAY) 10%
3 min readTeplitsky Liane Rae (Chief Operating Officer) purchased 2,070 shares of PULSE BIOSCIENCES, INC. (PLSE) at an average of $48.29 ($48.24–$48.35) across 2 trades over 2026-08-26 to 2026-08-28.
1 min readStock indices fluctuated as chipmakers rose while software companies declined. S&P 500 Q2 earnings are tracking at +32% growth, with AI infrastructure contributing 60%. Sandisk (SNDK) led gains, up +10%, while Datadog (DDOG) led losses, down -3%. EyePoint (EYPT) dropped -71% after a failed trial. Constellation Brands (STZ) fell -5% after Berkshire Hathaway sold its stake.
6 min read
